Integra LifeSciences launches Revize™/ Revize™-X Collagen Matrix for Plastic and Reconstructive Surgery
October 06 2017 - 8:30AM
Integra LifeSciences Holdings Corporation (Nasdaq:IART), a
leading global medical technology company, today announced the
launch of Revize™ / Revize-X™ Collagen Matrix, its latest offering
in tissue-building solutions for plastic and reconstructive
surgery. Revize and Revize-X are derived from fetal bovine dermis,
which is rich in Type III collagen. Revize-X is an expandable
matrix that provides up to twice the initial coverage area once
hydrated and fully expanded. It features a meshing pattern which
allows for vascular ingrowth and increased conformability.
“The Revize and Revize-X products provide new, innovative
solutions to plastic and reconstructive surgeons for use in their
private practices. Our entry into this space will provide surgeons
with leading edge technology for patients undergoing cosmetic
revisionary procedures,” said Robert T. Davis, Jr., corporate vice
president and president, Orthopedics and Tissue Technologies.
About Revize and Revize-X
Revize / Revize-X is intended for implantation to reinforce soft
tissue where weakness exists and for surgical repair of damaged or
ruptured soft tissue membranes. Revize / Revize-X is specifically
indicated for plastic and reconstructive surgery. About
Integra Integra LifeSciences is dedicated to limiting
uncertainty for clinicians, so they can concentrate on providing
the best patient care. Integra offers innovative solutions,
including leading plastic and regenerative technologies, in
specialty surgical solutions, and orthopedics and tissue
technologies. For more information, please visit
www.integralife.com.This news release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include, but are not
limited to, statements concerning the products and services
provided by Integra. Such forward looking statements involve risks
and uncertainties that could cause actual results to differ
materially from predicted or expected results. Among other things,
the willingness of surgical professionals to use Integra products
may affect the prospects for their use in surgical procedures. In
addition, the economic, competitive, governmental, technological
and other factors, identified under the heading "Risk Factors"
included in Item IA of Integra's Annual Report on Form 10-K for the
year ended December 31, 2016 and information contained in
subsequent filings with the Securities and Exchange Commission
could affect actual results.
CONTACT: Integra LifeSciences Holdings
Company
Investors:Michael Beaulieu+ 609 750
2827michael.beaulieu@integralife.com
Media: Laurene Isip (U.S.)+ 609 750
7984laurene.isip@integralife.com
Integra LifeSciences (NASDAQ:IART)
Historical Stock Chart
From Aug 2024 to Sep 2024
Integra LifeSciences (NASDAQ:IART)
Historical Stock Chart
From Sep 2023 to Sep 2024